Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2725 participants.

Also called NCT02164864

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,725 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02164864
  • EudraCT 2013-003201-26
Other papers using this trial's data
  • Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI The American journal of medicine, 2020-11 DOI, PubMed 32389658
  • Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation The New England journal of medicine, 2017-10-19 DOI, PubMed 28844193
  • Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial Circulation. Cardiovascular interventions, 2020-04 DOI, PubMed 32252548
  • Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI JACC. Cardiovascular interventions, 2019-08-26 DOI, PubMed 31439336

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02164864. Randomized; no masking; primary purpose treatment. Start 2014-07-22 (actual); primary completion 2017-06-05 (actual). Results posted on 2018-07-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
Intervention (Drug)
Dabigatran Etexilate 110mg
Intervention (Drug)
Warfarin 3mg
Intervention (Drug)
Aspirin
Intervention (Drug)
Dabigatran Etexilate 150mg
Intervention (Drug)
Clopidogrel or Ticagrelor
Intervention (Drug)
Clopidogrel or Ticagrelor
Intervention (Drug)
Warfarin 5mg
Intervention (Drug)
Clopidogrel or Ticagrelor
Intervention (Drug)
Warfarin 1mg
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02164864
Content hash
869c9a59323717f85b97ceed7d76a8e949212b255484361d124ff5b44b14daa8